A Digital Publication for the Practicing Medical Specialist, Industry Executive & Investor

Global Legionella Testing Market to Reach $421.9 Million by 2027

December 24, 2020

Global Legionella Testing Market to Reach $421.9 Million by 2027: Amid the COVID-19 crisis, the global market for Legionella Testing estimated at US$244.5 Million in the year 2020, is projected to reach a revised size of US$421.9 Million by 2027, growing at a CAGR of 8.1% over the analysis period 2020-2027.

Culture Methods, one of the segments analyzed in the report, is projected to record a 8.4% CAGR and reach US$93 Million by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Urinary Antigen Test (UAT) segment is readjusted to a revised 8.4% CAGR for the next 7-year period.

The U.S. Market is Estimated at $66.1 Million, While China is Forecast to Grow at 12.3% CAGR

The Legionella Testing market in the U.S. is estimated at US$66.1 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$95.7 Million by the year 2027 trailing a CAGR of 12.2% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 4.4% and 7.2% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 5.3% CAGR.

Serology Segment to Record 7.1% CAGR

In the global Serology segment, USA, Canada, Japan, China and Europe will drive the 6.6% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$14.6 Million in the year 2020 will reach a projected size of US$22.7 Million by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$58.6 Million by the year 2027, while Latin America will expand at a 8.4% CAGR through the analysis period.

Competitors identified in this market include, among others:

  • Becton, Dickinson & Company
  • bioMerieux SA
  • Bio-Rad Laboratories, Inc.
  • IDEXX Laboratories, Inc.
  • Qiagen NV
  • Thermo Fisher Scientific, Inc.

Key Topics Covered:

I. INTRODUCTION, METHODOLOGY & REPORT SCOPE

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW

  • Global Competitor Market Shares
  • Legionella Testing Competitor Market Share Scenario Worldwide (in %): 2019 & 2025
  • Impact of Covid-19 and a Looming Global Recession

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

4. GLOBAL MARKET PERSPECTIVE

III. MARKET ANALYSIS

IV. COMPETITION

  • Total Companies Profiled: 41

For more information about this report visit here.

 

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

The Evolut ™ FX+ TAVR system leverages market-leading valve performance with addition of larger windows to facilitate coronary access
The study was an analysis of AstraZeneca’s Phase 2 52-Week clinical trial of tralokinumab in patients with Idiopathic Pulmonary Fibrosis (IPF). The patient data from the trial was processed with Brainomix’s e-Lung tool. The tool is uniquely powered by the weighted reticulovascular score (WRVS), a novel biomarker that incorporates reticular opacities and vascular structures of the lung.
“Since the algorithm for matching patients with donors is changing across for all organs, this was a prime time to better understand whether transplant team decisions to accept a donated organ varied by patient race and gender,” she said. “We wanted to understand how the process of receiving a transplant after listing varied by race and gender, and the combination of the two, so that steps can be taken to make that process more equitable," said Khadijah Breathett, MD.
The Mount Sinai study found that primary care physicians’ approach reflects a dearth of evidence-based guidance for lung cancer screening shared decision-making in patients with complex comorbidities
This is the first ever transplantation of a genetically engineered porcine kidney into a living human recipient.

By using this website you agree to accept Medical Device News Magazine Privacy Policy